Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson's disease models

被引:13
|
作者
Liu, Lan-Xiang [1 ]
Du, Dan [1 ]
Wang, Zhan-Qiu [1 ]
Fang, Yuan [1 ]
Zheng, Tao [1 ]
Dong, Yan-Chao [2 ]
Shi, Qing-Lei [3 ]
Zhao, Min [4 ]
Xiao, Fang [4 ]
Du, Juan [5 ]
机构
[1] Qinhuangdao Municipal 1 Hosp, Dept Magnet Resonance Imaging, Qinhuangdao, Hebei, Peoples R China
[2] Qinhuangdao Municipal 1 Hosp, Dept Intervent, Qinhuangdao, Hebei, Peoples R China
[3] Siemens Ltd, Beijing, Peoples R China
[4] Qinhuangdao Municipal 1 Hosp, Dept Pathol, Qinhuangdao, Hebei, Peoples R China
[5] Hebei Med Univ, Shijiazhuang, Hebei, Peoples R China
关键词
nerve regeneration; fractional anisotropy; T2*; rotenone; 6-hydroxydopamine; Parkinson's disease; magnetic resonance imaging; diffusion tensor imaging; dopaminergic neurons; neural regeneration; WHITE-MATTER CHANGES; SUBSTANTIA-NIGRA; COMPLEX-I; DEGENERATION; MECHANISMS; DEPOSITION; TOXICITY; SYSTEM;
D O I
10.4103/1673-5374.235076
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Rotenone and 6-hydroxydopamine are two drugs commonly used to generate Parkinson's disease animal models. They not only achieve degenerative changes of dopaminergic neurons in the substantia nigra, but also satisfy the requirements for iron deposition. However, few studies have compared the characteristics of these two models by magnetic resonance imaging. In this study, rat models of Parkinson's disease were generated by injection of 3 mu g rotenone or 10 mu g 6-hydroxydopamine into the right substantia nigra. At 1, 2, 4, and 6 weeks after injection, coronal whole-brain T2-weighted imaging, transverse whole-brain T2-weighted imaging, and coronal diffusion tensor weighted imaging were conducted to measure fractional anisotropy and T2* values at the injury site. The fractional anisotropy value on the right side of the substantia nigra was remarkably lower at 6 weeks than at other time points in the rotenone group. In the 6-hydroxydopamine group, the fractional anisotropy value was decreased, but T2* values were increased on the right side of the substantia nigra at 1 week. Our findings confirm that the 6-hydroxydopamine-induced model is suitable for studying dopaminergic neurons over short periods, while the rotenone-induced model may be appropriate for studying the pathological and physiological processes of Parkinson's disease over long periods.
引用
收藏
页码:1276 / 1280
页数:5
相关论文
共 50 条
  • [41] Ellagic Acid Protects the Brain Against 6-Hydroxydopamine Induced Neuroinflammation in a Rat Model of Parkinson's Disease
    Farbood, Yaghoob
    Sarkaki, Alireza
    Dolatshahi, Mojtaba
    Mansouri, Seyed Mohammad Taqhi
    Khodadadi, Ali
    BASIC AND CLINICAL NEUROSCIENCE, 2015, 6 (02) : 83 - 90
  • [42] Characterisation of Behavioural and Neurodegenerative Changes Induced by Intranigral 6-Hydroxydopamine Lesions in a Mouse Model of Parkinson's Disease
    Grealish, S.
    Mattsson, B.
    Draxler, P.
    Bjorklund, A.
    MOVEMENT DISORDERS, 2010, 25 : S634 - S634
  • [43] Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: Implications for treating Parkinson's disease?
    Wang, S
    Hu, LF
    Yang, Y
    Ding, JH
    Hu, G
    NEUROPHARMACOLOGY, 2005, 48 (07) : 984 - 992
  • [44] Characterisation of Behavioural and Neurodegenerative Changes Induced by Intranigral 6-Hydroxydopamine Lesions in a Mouse Model of Parkinson's Disease
    Grealish, S.
    Mattsson, B.
    Draxler, P.
    Bjorklund, A.
    MOVEMENT DISORDERS, 2010, 25 : S633 - S633
  • [45] Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat:: an animal model of Parkinson's disease
    Díaz, MR
    Abdala, P
    Barroso-Chinea, P
    Obeso, J
    González-Hernández, T
    BEHAVIOURAL BRAIN RESEARCH, 2001, 122 (01) : 79 - 92
  • [46] Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease
    Grealish, Shane
    Mattsson, Bengt
    Draxler, Peter
    Bjorklund, Anders
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2010, 31 (12) : 2266 - 2278
  • [47] Parkinson Disease-Modification Encompassing Rotenone and 6-Hydroxydopamine Neurotoxicity by the Microtubule-Protecting Drug Candidate SKIP
    Ivashko-Pachima, Yanina
    Seroogy, Kim B.
    Sharabi, Yehonatan
    Gozes, Illana
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2021, 71 (08) : 1515 - 1524
  • [48] Parkinson Disease-Modification Encompassing Rotenone and 6-Hydroxydopamine Neurotoxicity by the Microtubule-Protecting Drug Candidate SKIP
    Yanina Ivashko-Pachima
    Kim B. Seroogy
    Yehonatan Sharabi
    Illana Gozes
    Journal of Molecular Neuroscience, 2021, 71 : 1515 - 1524
  • [49] Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease
    Casteels, Cindy
    Lauwers, Erwin
    Bormans, Guy
    Baekelandt, Veerle
    Van Laere, Koen
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (01) : 124 - 134
  • [50] Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson's Disease
    Pislar, Anja
    Tratnjek, Larisa
    Glavan, Gordana
    Zivin, Marko
    Kos, Janko
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2018, 11